Liposomal clodronate treatment for tumour macrophage depletion in dogs with soft-tissue sarcoma

Veterinary and Comparative Oncology

Volumn 11, Issue 4, 2013, Pages 296-305

  Guth, A M ^a   Hafeman, S D ^a   Elmslie, R E ^b   Dow, S W ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b Veterinary Referral Center of Colorado   (United States)

Author keywords

Cancer; Canine; Immune; Macrophage; Myeloid

Indexed keywords

CANIS FAMILIARIS; RODENTIA;

CLODRONIC ACID; CYTOKINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CANINE; DOG; DOG DISEASE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNE; MACROPHAGE; MALE; METABOLISM; MYELOID; NEOPLASM; PHYSIOLOGY; SARCOMA;

CANCER; CANINE; IMMUNE; MACROPHAGE; MYELOID;

ANIMALS; CLODRONIC ACID; CYTOKINES; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION; MACROPHAGES; MALE; SARCOMA;

EID: 84886639624     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2012.00319.x     Document Type: Article

References (44)

1. Halin S, Rudolfsson SH, Van Rooijen N and Bergh A. Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model. Neoplasia 2009; 11: 177-186.
2. Oosterling SJ, van der Bij GJ, Meijer GA, Tuk CW, van Garderen E, van Rooijen N, Meijer S, van der Sijp JR, Beelen RH and van Egmond M. Macrophages direct tumour histology and clinical outcome in a colon cancer model. Journal of Pathology 2005; 207: 147-155.
3. Kimura YN, Watari K, Fotovati A, Hosoi F, Yasumoto K, Izumi H, Kohno K, Umezawa K, Iguchi H, Shirouzu K, Takamori S, Kuwano M and Ono M. Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis. Cancer Science 2007; 98: 2009-2018.
4. Bolat F, Kayaselcuk F, Nursal TZ, Yagmurdur MC, Bal N and Demirhan B. Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: correlations with prognostic parameters. Journal of Experimetal Clinical Cancer Research 2006; 25: 365-372.
5. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC and Gascoyne RD. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. The New England Journal of Medicine 2010; 362: 875-885.
6. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ and Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunology Immunotherapy 2009; 58: 49-59.
7. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G and Rivoltini L. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007; 25: 2546-2553.
8. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP and Gabrilovich DI. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. Journal of Immunology 2001; 166: 678-689.
9. Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kubler H, Yancey D, Dahm P and Vieweg J. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clinical Cancer Research 2008; 14: 8270-8278.
10. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP, Greten TF and Korangy F. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008; 135: 234-243.
11. Krol M, Pawlowski KM, Dolka I, Musielak O, Majchrzak K, Mucha J and Motyl T. Density of Gr1-positive myeloid precursor cells, p-STAT3 expression and gene expression pattern in canine mammary cancer metastasis. Veterinary Research Communications 2011; 35: 409-423.
12. Krol M, Pawlowski KM, Majchrzak K, Dolka I, Abramowicz A, Szyszko K and Motyl T. Density of tumor-associated macrophages (TAMs) and expression of their growth factor receptor MCSF-R and CD14 in canine mammary adenocarcinomas of various grade of malignancy and metastasis. Polish Journal of Veterinary Sciences 2011; 14: 3-10.
13. Lee C-C, Liu K-J Liu, Chen L-L, Wu Y-C and Huang T-S. Tumor necrosis factor-α, interleukin-8 and interleukin-6 are involved in vascular endothelial cell capillary tube and network formation induced by tumor-associated macrophages. Journal of Cancer Molecules 2006; 2: 155-160.
14. Giraudo E, Inoue M and Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. The Journal Clinical Investigation 2004; 114: 623-633.
15. Watanabe S, Deguchi K, Zheng R, Tamai H, Wang LX, Cohen PA and Shu S. Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. Journal of Immunology 2008; 181: 3291-3300.
16. Hanson EM, Clements VK, Sinha P, Ilkovitch D and Ostrand-Rosenberg S. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. Journal of Immunology 2009; 183: 937-944.
17. Fujimura T, Mahnke K and Enk AH. Myeloid derived suppressor cells and their role in tolerance induction in cancer. Journal of Dermatological Science 2010; 59: 1-6.
18. Nagaraj S, Schrum AG, Cho HI, Celis E and Gabrilovich DI. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. Journal of Immunology 2010; 184: 3106-3116.
19. Srivastava MK, Sinha P, Clements VK, Rodriguez P and Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Research 2010; 70: 68-77.
20. Ye XZ, Yu SC and Bian XW. Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis. Journal of Genetics and Genomics 2010; 37: 423-430.
21. Lee C-C, Liu K-J and Huang T-S. Tumor-associated macrophage: its role in tumor angiogenesis. Journal of Cancer Molecules 2006; 2: 135-140.
22. Lewis CE and Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Research 2006; 66: 605-612.
23. Sica A, Schioppa T, Mantovani A and Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. European Journal of Cancer 2006; 42: 717-727.
24. Sica A and Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. The Journal of Clinical Investigation 2007; 117: 1155-1166.
25. Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjallman AH, Ballmer-Hofer K and Schwendener RA. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. British Journal of Cancer 2006; 95: 272-281.
26. Gazzaniga S, Bravo AI, Guglielmotti A, van Rooijen N, Maschi F, Vecchi A, Mantovani A, Mordoh J and Wainstok R. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. Journal of Investigative Dermatology 2007; 127: 2031-2041.
27. Hiraoka K, Zenmyo M, Watari K, Iguchi H, Fotovati A, Kimura YN, Hosoi F, Shoda T, Nagata K, Osada H, Ono M and Kuwano M. Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Science 2008; 99: 1595-1602.
28. Miselis NR, Wu ZJ, Van Rooijen N and Kane AB. Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Molecular Cancer Therapeutics 2008; 7: 788-799.
29. Lepique AP, Daghastanli KR, Cuccovia IM and Villa LL. HPV16 tumor associated macrophages suppress antitumor T cell responses. Clinical Cancer Research 2009; 15: 4391-4400.
30. Van Rooijen N and Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. Journal of Immunological Methods 1994; 174: 83-93.
31. Alves-Rosa F, Stanganelli C, Cabrera J, van Rooijen N, Palermo MS and Isturiz MA. Treatment with liposomal clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model. Blood 2000; 96: 2834-2840.
32. Jordan MB, van Rooijen N, Izui S, Kappler J and Marrack P. Liposomal clodronate as a novel agent for treating autoimmune hemolytic anemia in a mouse model. Blood 2003; 101: 594-601.
33. Nakao S, Kuwano T, Tsutsumi-Miyahara C, Ueda S, Kimura YN, Hamano S, Sonoda KH, Saijo Y, Nukiwa T, Strieter RM, Ishibashi T, Kuwano M and Ono M. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. The Journal of Clinical Investigation 2005; 115: 2979-2991.
34. Meng Y, Beckett MA, Liang H, Mauceri HJ, van Rooijen N, Cohen KS and Weichselbaum RR. Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy. Cancer Research 2010; 70: 1534-1543.
35. Mathes M, Jordan M and Dow S. Evaluation of liposomal clodronate in experimental spontaneous autoimmune hemolytic anemia in dogs. Experimental Hematology 2006; 34: 1393-1402.
36. Hafeman S, London C, Elmslie R and Dow S. Evaluation of liposomal clodronate for treatment of malignant histiocytosis in dogs. Cancer Immunol Immunother 2009; 59: 441-452.
37. Veterinary Co-operative Oncology Group. Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Veterinary and Comparative Oncology 2004; 2: 195-213.
38. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 2009; 45: 228-247.
39. Kamstock D, Guth A, Elmslie R, Kurzman I, Liggitt D, Coro L, Fairman J and Dow S. Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma. Cancer Gene Therapy 2006; 13: 306-317.
40. Tacke F, Ginhoux F, Jakubzick C, van Rooijen N, Merad M and Randolph GJ. Immature monocytes acquire antigens from other cells in the bone marrow and present them to T cells after maturing in the periphery. The Journal of Experimental Medicine 2006; 203: 583-597.
41. Tacke F and Randolph GJ. Migratory fate and differentiation of blood monocyte subsets. Immunobiology 2006; 211: 609-618.
42. Kjelgaard-Hansen M, Goggs R, Wiinberg B and Chan DL. Use of serum concentrations of interleukin-18 and monocyte chemoattractant protein-1 as prognostic indicators in primary immune-mediated hemolytic anemia in dogs. Journal of Veterinary Internal Medicine/American College of Veterinary Internal Medicine 2011; 25: 76-82.
43. Dow SW, Fradkin LG, Liggitt DH, Willson AP, Heath TD and Potter TA. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. Journal of Immunology 1999; 163: 1552-1561.
44. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG and Strieter RM. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258: 1798-1801.